Business Description
Matinas BioPharma Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US5768103039
Total Employee Number:
2Description
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.02 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | -0.18 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 39.9 | |||||
3-Year EPS without NRI Growth Rate | 37.3 | |||||
3-Year FCF Growth Rate | 34.8 | |||||
3-Year Book Growth Rate | -55.3 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.33 | |||||
9-Day RSI | 27.3 | |||||
14-Day RSI | 30.54 | |||||
3-1 Month Momentum % | 37.18 | |||||
6-1 Month Momentum % | 4.38 | |||||
12-1 Month Momentum % | -27.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.32 | |||||
Quick Ratio | 1.32 | |||||
Cash Ratio | 1.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.8 | |||||
Shareholder Yield % | 49.4 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -187.74 | |||||
ROA % | -114.74 | |||||
ROIC % | -143.09 | |||||
3-Year ROIIC % | -189.18 | |||||
ROC (Joel Greenblatt) % | -539.76 | |||||
ROCE % | -93.63 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.76 | |||||
Price-to-Tangible-Book | 2.97 | |||||
EV-to-EBIT | -0.15 | |||||
EV-to-EBITDA | -0.17 | |||||
EV-to-Forward-Revenue | 71.77 | |||||
EV-to-FCF | -0.16 | |||||
Earnings Yield (Greenblatt) % | -666.67 | |||||
FCF Yield % | -289.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:MTNB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Matinas BioPharma Holdings Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.99 | ||
| Beta | 3.0514 | ||
| 3-Year Sharpe Ratio | -0.32 | ||
| 3-Year Sortino Ratio | -0.47 | ||
| Volatility % | 136.43 | ||
| 14-Day RSI | 30.54 | ||
| 14-Day ATR ($) | 0.094743 | ||
| 20-Day SMA ($) | 0.591252 | ||
| 12-1 Month Momentum % | -27.98 | ||
| 52-Week Range ($) | 0.3084 - 3.09 | ||
| Shares Outstanding (Mil) | 6.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Matinas BioPharma Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Matinas BioPharma Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 116 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 28 days | ||
| General meeting for 2025 | 2026-07-21 09:00 | In 5 days | ||
| First quarter earnings results for 2026 | 2026-05-08 | 0.65 (-2.27%) | ||
| Annual report for 2025 | 2026-03-31 | 0.57 (-3.08%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 1.28 (+7.56%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 1.56 (+2.63%) | ||
| General meeting for 2024 | 2025-06-23 09:00 | 0.91 (+1.55%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 0.69 (+0.39%) | ||
| Annual report for 2024 | 2025-04-15 | 0.58 (-3.33%) |
Show
Entries
Matinas BioPharma Holdings Inc Frequently Asked Questions
What is Matinas BioPharma Holdings Inc(MTNB)'s stock price today?
The current price of MTNB is $0.36. The 52 week high of MTNB is $3.09 and 52 week low is $0.31.
When is next earnings date of Matinas BioPharma Holdings Inc(MTNB)?
The next earnings date of Matinas BioPharma Holdings Inc(MTNB) is 2026-08-14 Est..
Does Matinas BioPharma Holdings Inc(MTNB) pay dividends? If so, how much?
Matinas BioPharma Holdings Inc(MTNB) does not pay dividend.
Guru Commentaries on AMEX:MTNB
No articles.
Press Release
Articles on Matinas BioPharma Holdings Inc
Headlines
See More- 1
Jul 13, 2026
GH Power, Matinas BioPharma join forces to create NYSE-listed clean energy company
Seeking Alpha • 3:26pm
Jun 26, 2026
Matinas BioPharma faces NYSE notice over equity shortfall; gets until 2027 to comply
Seeking Alpha • 4:38pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers